AstraZeneca’s Imfinzi/Treme Combo Fails To Match Leaders In First-Line Lung Cancer
Too Little, Too Late In Crowded Market
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.
The immunotherapy drugs fall short of the standard set by Keytruda, but could gain some traction in non-squamous patient group.